Oral Supplementation of Sodium Butyrate Attenuates the Progression of Non-Alcoholic Steatohepatitis

Sodium butyrate (SoB) supplementation has been suggested to attenuate the development of non-alcoholic fatty liver disease (NAFLD). Here, we determined the therapeutic potential of SoB on NAFLD progression and molecular mechanism involved. Eight-week old C57BL/6J mice were pair-fed a fat-, fructose-...

Descripción completa

Detalles Bibliográficos
Autores principales: Baumann, Anja, Jin, Cheng Jun, Brandt, Annette, Sellmann, Cathrin, Nier, Anika, Burkard, Markus, Venturelli, Sascha, Bergheim, Ina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231312/
https://www.ncbi.nlm.nih.gov/pubmed/32235497
http://dx.doi.org/10.3390/nu12040951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231312/
https://www.ncbi.nlm.nih.gov/pubmed/32235497
http://dx.doi.org/10.3390/nu12040951

Ejemplares similares